The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4848-4858

  Mendel, Dirk B ^a   Schreck, Randall E ^a   West, David C ^a   Li, Guangmin ^a   Strawn, Laurie M ^a   Tanciongco, Sheila S ^a   Vasile, Stefan ^a   Shawver, Laura K ^a   Cherrington, Julie M ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

3T3 CELLS; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CELL MEMBRANE; CELL SEPARATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLES; KINETICS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED; UMBILICAL CORD;

EID: 0034488898     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Anti-angiogenesis: New concept for therapy of solid tumors
2. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
3. Prolonged tumor dormancy by prevention of neovascularization in the vitreous
4. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
5. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma
6. Angiogenesis and tumor metastasis
7. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents
8. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
9. Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma
10. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
11. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
12. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
13. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
14. Tumor angiogenesis as a prognostic factor in oral cavity tumors
15. Molecular and biological properties of vascular endothelial growth factor
16. Is angiogenesis inhibition the holy grail of cancer therapy?
17. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
18. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
19. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
20. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
21. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
22. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
23. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
24. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
25. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
26. 121
27. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
28. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
29. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
30. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel FLK-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy
31. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor (VEGF) receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
32. The pharmacokinetic and pharmacodynamic properties of SU5416, a novel VEGF receptor inhibitor
33. A multicenter dose escalating study of SU5416 in patients with cutaneous AIDS-related Kaposi’s sarcoma
34. Phase I dose-escalating trial of SU5416, a novel inhibitor in patients with advanced malignancies
35. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
36. New colorimetric cytotoxicity assay for anticancer-drug screening
37. The attraction of proteins for small molecules and ions
38. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites
39. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation
40. SU6668 is a potent anti-angiogenic and anti-tumor agent which induces regression of established tumors
41. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization
42. Tyrosine kinase inhibitors, 15.4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
43. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors
44. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds
45. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
46. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor sub-family of protein tyrosine kinases
47. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl) amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
48. Inhibition of p56(lck) tyrosine kinase by isothiazolones